pubmed-article:19589485 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:19589485 | lifeskim:mentions | umls-concept:C0009450 | lld:lifeskim |
pubmed-article:19589485 | lifeskim:mentions | umls-concept:C0229671 | lld:lifeskim |
pubmed-article:19589485 | lifeskim:mentions | umls-concept:C0009566 | lld:lifeskim |
pubmed-article:19589485 | lifeskim:mentions | umls-concept:C0441889 | lld:lifeskim |
pubmed-article:19589485 | lifeskim:mentions | umls-concept:C1550587 | lld:lifeskim |
pubmed-article:19589485 | lifeskim:mentions | umls-concept:C0966897 | lld:lifeskim |
pubmed-article:19589485 | lifeskim:mentions | umls-concept:C2826293 | lld:lifeskim |
pubmed-article:19589485 | lifeskim:mentions | umls-concept:C1705576 | lld:lifeskim |
pubmed-article:19589485 | pubmed:issue | 8 | lld:pubmed |
pubmed-article:19589485 | pubmed:dateCreated | 2009-7-10 | lld:pubmed |
pubmed-article:19589485 | pubmed:abstractText | The association of iron overload with complications of allogeneic hematopoietic stem cell transplantation (HSCT) has been suggested in previous studies. Because hepcidin plays a central role in the regulation of iron homeostasis, we analyzed the association between pretransplant serum hepcidin-25 levels and early infectious complications after allogeneic HSCT. We studied 55 consecutive adult patients with a median age of 47 years (range: 20-64 years) who underwent allogeneic HSCT for hematologic malignancies at our institution. Thirty-two patients had myelogenous malignancies; the remaining 23 had lymphogenous malignancies. The median pretransplant serum hepcidin level of patients in the study was 21.6 ng/mL (range: 1.4-371 ng/mL), which was comparable to that of healthy volunteers (median: 19.1 ng/mL [range: 2.3-37 ng/mL]; n = 17). When cumulative incidences of documented bacterial and cytomegalovirus (CMV) infections at day 100 were compared according to pretransplant hepcidin-25 levels, the incidence of bacterial, but not CMV, infection, was significantly higher in the high-hepcidin group (> or = 50 ng/mL; n = 17) than in the low-hepcidin group (<50 ng/mL; n = 38) (65% [95% confidence interval, 38%-82%] versus 11% [3%-23%]; P < .001). This finding was confirmed by multivariate Cox analysis adjusted for confounders, including pretransplant ferritin and C-reactive protein (CRP) levels. No fungal infection was documented in either group. These results suggest that the pretransplant serum hepcidin-25 level may be a useful marker for predicting the risk of early bacterial complications after allogeneic HSCT. Larger prospective studies are, however, warranted to confirm our findings. | lld:pubmed |
pubmed-article:19589485 | pubmed:language | eng | lld:pubmed |
pubmed-article:19589485 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:19589485 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:19589485 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:19589485 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:19589485 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:19589485 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:19589485 | pubmed:month | Aug | lld:pubmed |
pubmed-article:19589485 | pubmed:issn | 1523-6536 | lld:pubmed |
pubmed-article:19589485 | pubmed:author | pubmed-author:MatsuoKeitaro... | lld:pubmed |
pubmed-article:19589485 | pubmed:author | pubmed-author:UchiyamaTakas... | lld:pubmed |
pubmed-article:19589485 | pubmed:author | pubmed-author:KawabataHiros... | lld:pubmed |
pubmed-article:19589485 | pubmed:author | pubmed-author:KondoTadakazu... | lld:pubmed |
pubmed-article:19589485 | pubmed:author | pubmed-author:IchinoheTatsu... | lld:pubmed |
pubmed-article:19589485 | pubmed:author | pubmed-author:IshikawaTakay... | lld:pubmed |
pubmed-article:19589485 | pubmed:author | pubmed-author:YamashitaKouh... | lld:pubmed |
pubmed-article:19589485 | pubmed:author | pubmed-author:TomosugiNaohi... | lld:pubmed |
pubmed-article:19589485 | pubmed:author | pubmed-author:MizumotoChisa... | lld:pubmed |
pubmed-article:19589485 | pubmed:author | pubmed-author:KandaJunyaJ | lld:pubmed |
pubmed-article:19589485 | pubmed:author | pubmed-author:TsuchidaHidey... | lld:pubmed |
pubmed-article:19589485 | pubmed:issnType | Electronic | lld:pubmed |
pubmed-article:19589485 | pubmed:volume | 15 | lld:pubmed |
pubmed-article:19589485 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:19589485 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:19589485 | pubmed:pagination | 956-62 | lld:pubmed |
pubmed-article:19589485 | pubmed:meshHeading | pubmed-meshheading:19589485... | lld:pubmed |
pubmed-article:19589485 | pubmed:meshHeading | pubmed-meshheading:19589485... | lld:pubmed |
pubmed-article:19589485 | pubmed:meshHeading | pubmed-meshheading:19589485... | lld:pubmed |
pubmed-article:19589485 | pubmed:meshHeading | pubmed-meshheading:19589485... | lld:pubmed |
pubmed-article:19589485 | pubmed:meshHeading | pubmed-meshheading:19589485... | lld:pubmed |
pubmed-article:19589485 | pubmed:meshHeading | pubmed-meshheading:19589485... | lld:pubmed |
pubmed-article:19589485 | pubmed:meshHeading | pubmed-meshheading:19589485... | lld:pubmed |
pubmed-article:19589485 | pubmed:meshHeading | pubmed-meshheading:19589485... | lld:pubmed |
pubmed-article:19589485 | pubmed:meshHeading | pubmed-meshheading:19589485... | lld:pubmed |
pubmed-article:19589485 | pubmed:meshHeading | pubmed-meshheading:19589485... | lld:pubmed |
pubmed-article:19589485 | pubmed:meshHeading | pubmed-meshheading:19589485... | lld:pubmed |
pubmed-article:19589485 | pubmed:meshHeading | pubmed-meshheading:19589485... | lld:pubmed |
pubmed-article:19589485 | pubmed:meshHeading | pubmed-meshheading:19589485... | lld:pubmed |
pubmed-article:19589485 | pubmed:meshHeading | pubmed-meshheading:19589485... | lld:pubmed |
pubmed-article:19589485 | pubmed:meshHeading | pubmed-meshheading:19589485... | lld:pubmed |
pubmed-article:19589485 | pubmed:meshHeading | pubmed-meshheading:19589485... | lld:pubmed |
pubmed-article:19589485 | pubmed:meshHeading | pubmed-meshheading:19589485... | lld:pubmed |
pubmed-article:19589485 | pubmed:year | 2009 | lld:pubmed |
pubmed-article:19589485 | pubmed:articleTitle | Clinical significance of serum hepcidin levels on early infectious complications in allogeneic hematopoietic stem cell transplantation. | lld:pubmed |
pubmed-article:19589485 | pubmed:affiliation | Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan. jkanda16@kuhp.kyoto-u.ac.jp | lld:pubmed |
pubmed-article:19589485 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:19589485 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:19589485 | lld:pubmed |